7月24日，Hims & Hers Health盘中上涨5.04%，报32.7美元/股，成交额7137.57万美元。
消息面上，FDA顾问委员会投票决定将Bpc-157肽列入允许药房配制的清单。此前该公司在小组会议中积极呼吁FDA扩大对特定肽类药物的可及性，最终获得监管层积极信号。若相关准入正式落地，将有望拓宽公司远程医疗平台的处方药品种覆盖范围，为其体重管理等业务带来增量空间。
Hims & Hers Health Inc是一家多专业远程医疗平台，将消费者与持牌医疗保健专业人员联系起来，使他们能够获得与心理健康、性健康、皮肤病学、头发护理等相关的多种疾病的高质量医疗服务。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.